PanTera’s Funding Signals a Turning Point for Cancer Care
PanTera, the joint venture between IBA and SCK CEN, has taken a major step toward expanding access to actinium-225, a radioisotope central to new, highly targeted cancer treatments. The company has secured EUR 93 million in an oversubscribed Series A round led by EQT Life Sciences, valuing PanTera at roughly EUR 280 million post-money. The raise is more than a financial milestone—it’s a concrete move to meet fast-rising demand for targeted therapies and to bring a reliable, clinical-grade supply of actinium-225 to market.
How the Investment Reshapes Operations
Before this round, IBA held a 47.8% stake in PanTera; following the close, its participation adjusts to 31.3%. This change is expected to generate an estimated EUR 23 million in profit for IBA over the next three years. Most of the new capital will go toward building a purpose-built production facility—critical infrastructure for scaling the manufacturing of actinium-225 to consistent, clinical standards. In short: a larger, steadier supply, produced at quality levels fit for widespread use.
Why Actinium-225 Matters
Actinium-225 sits at the heart of Targeted Alpha Therapy (TAT), which delivers radiation directly to cancer cells while sparing as much healthy tissue as possible. Interest is accelerating as pharmaceutical companies expand clinical trials across multiple cancer types and push toward regulatory approvals. The problem is supply. Existing production methods have struggled to keep up, creating a material global shortage at the very moment demand is climbing.
PanTera’s Production Approach
To address that gap, PanTera uses a proprietary photo-nuclear “gamma” method that converts Radium-226 into Radium-225, which then decays into actinium-225. The approach is designed to deliver dependable output at scale. PanTera is targeting commercial readiness in 2028–2029 and aims to produce more than 100 Curies of clinical-grade actinium-225 per year by 2029. At that level, the company estimates it could support treatment for over 100,000 patients annually—shifting the conversation from scarcity to access.
Partnerships and Near-Term Steps
Alongside the financing, PanTera is lining up additional support and supply avenues. The company has partnered with TerraPower Isotopes to add a supplementary source of actinium-225 through an alternative production route, with a target of 1.5–2 Curies annually starting in early 2025. For context, current global supply averages around 3 Curies a year, which underscores how meaningful even an incremental increase can be while larger-scale capacity comes online.
What the CEO Envisions
For CEO Sven Van den Berghe, the round validates PanTera’s strategy: work with experienced partners, scale production responsibly, and move innovative cancer therapies from promise to practice. The funding is meant to speed up solutions to the actinium-225 shortage and, ultimately, broaden treatment access for patients who’ve been waiting on the supply to match the science.
Position in the Market—and Investor Backing
PanTera’s progress has drawn interest from leading investors, including Kurma Partners and Eurazeo. That backing reflects confidence in the company’s know-how and manufacturing path. With resources now in place and plans clearly sequenced, PanTera is entering a decisive phase—one focused on building capacity, executing partnerships, and establishing a stable, clinical-grade supply of actinium-225. The goal is straightforward: make a scarce therapy-ready isotope reliably available, so more patients can actually receive the treatments that depend on it.
Frequently Asked Questions
What does PanTera plan to do with the EUR 93 million?
The company will use the funds primarily to build and scale a dedicated facility for manufacturing actinium-225, ensuring a reliable supply for targeted cancer treatments.
Who led the Series A, and how was the round received?
EQT Life Sciences led the oversubscribed Series A round, which values PanTera at approximately EUR 280 million post-money.
Why is actinium-225 important in cancer care?
Actinium-225 powers Targeted Alpha Therapy, which directs radiation precisely to cancer cells while limiting exposure to healthy tissue—an approach now advancing through clinical trials.
When does PanTera expect commercial readiness?
PanTera is targeting commercial readiness in 2028–2029 and aims to produce more than 100 Curies of clinical-grade actinium-225 annually by 2029.
How does this financing affect IBA?
IBA’s stake in PanTera moves from 47.8% to 31.3%, and the transaction is expected to yield an estimated EUR 23 million benefit for IBA over the next three years.
